These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 23372484)

  • 1. FDA: Change Is Good.
    Carlson B
    Biotechnol Healthc; 2004 Mar; 1(1):27-30. PubMed ID: 23372484
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FDA's Unimproved Enforcement of Postmarketing Requirements and Commitments: Implications for Providers and Patients.
    Dauner DG; Dauner KN; Peterson ALH
    Res Social Adm Pharm; 2020 Jun; 16(6):844-847. PubMed ID: 31812502
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Export of pharmaceuticals and medical devices under the federal Food, Drug & Cosmetic Act: FDA's striking change in interpretation post-Shelhigh.
    Basile EM; Tolomeo D; Gluck E
    Food Drug Law J; 2009; 64(1):149-69. PubMed ID: 19998744
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The FDA and drug safety: a proposal for sweeping changes.
    Furberg CD; Levin AA; Gross PA; Shapiro RS; Strom BL
    Arch Intern Med; 2006 Oct; 166(18):1938-42. PubMed ID: 17030825
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An evaluation of the FDA's analysis of the costs and benefits of the graphic warning label regulation.
    Chaloupka FJ; Warner KE; Acemoğlu D; Gruber J; Laux F; Max W; Newhouse J; Schelling T; Sindelar J
    Tob Control; 2015 Mar; 24(2):112-9. PubMed ID: 25550419
    [TBL] [Abstract][Full Text] [Related]  

  • 6. What Commissioner Gottlieb's FDA Is Doing to Lower Prescription Drug Prices and Steps Congress Can Take to Help.
    Waxman H; Corr B; Martin K; Duong S
    Issue Brief (Commonw Fund); 2018 Apr; 2018():1-10. PubMed ID: 29992802
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Limits of FDA's Authority to Regulate Clinical Research Involving High-Throughput DNA Sequencing.
    Evans BJ
    Food Drug Law J; 2015; 70(2):259-87, ii. PubMed ID: 26302600
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An FDA Analysis of Formal Dispute Resolution in the Center for Drug Evaluation and Research: 2003 Through 2014.
    Sharma K; Harrington A; Worrell S; Bertha A
    Ther Innov Regul Sci; 2016 Nov; 50(6):697-704. PubMed ID: 30231744
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FDA's proposed regulations to expand access to investigational drugs for treatment use: the status quo in the guise of reform.
    Rossen BR
    Food Drug Law J; 2009; 64(1):183-223. PubMed ID: 19998746
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Examining the FDA's oversight of direct-to-consumer advertising.
    Gahart MT; Duhamel LM; Dievler A; Price R
    Health Aff (Millwood); 2003; Suppl Web Exclusives():W3-120-3. PubMed ID: 14527243
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interview with Janet Woodcock: progress on the FDA's critical path initiative.
    Woodcock J
    Biomark Med; 2009 Dec; 3(6):671-3. PubMed ID: 20477704
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FDA's expanding postmarket authority to monitor and publicize food and consumer health product risks: the need for procedural safeguards to reduce "transparency" policy harms in the post-9/11 regulatory environment.
    Roller ST; Pippins RR; Ngai JW
    Food Drug Law J; 2009; 64(3):577-98. PubMed ID: 19999646
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ensuring the safe and effective FDA regulation of fecal microbiota transplantation.
    Sachs RE; Edelstein CA
    J Law Biosci; 2015 Jul; 2(2):396-415. PubMed ID: 27774199
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The FDA's risk/benefit calculus in the approvals of Qsymia and Belviq: treating an obesity epidemic while avoiding another fen-phen.
    Azebu LM
    Food Drug Law J; 2014; 69(1):87-111, ii-iii. PubMed ID: 24772687
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Guidance of FDA's expectations of medical device manufacturers concerning the year 2000 date problem--FDA. Notice.
    Fed Regist; 1998 Jun; 63(121):34433-42. PubMed ID: 10180297
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmaceutical Drugs of Uncertain Value, Lifecycle Regulation at the US Food and Drug Administration, and Institutional Incumbency.
    Herder M
    Milbank Q; 2019 Sep; 97(3):820-857. PubMed ID: 31407412
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The FDA and genetic testing: improper tools for a difficult problem.
    Willmarth K
    J Law Biosci; 2015 Feb; 2(1):158-166. PubMed ID: 27774193
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Information to Improve Public Perceptions of the Food and Drug Administration (FDA's) Tobacco Regulatory Role.
    Osman A; Kowitt SD; Sheeran P; Jarman KL; Ranney LM; Goldstein AO
    Int J Environ Res Public Health; 2018 Apr; 15(4):. PubMed ID: 29661991
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Changes in long-acting β-agonist utilization after the FDA's 2010 drug safety communication.
    Hartung DM; Middleton L; Markwardt S; Williamson K; Ketchum K
    Clin Ther; 2015 Jan; 37(1):114-123.e1. PubMed ID: 25465946
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Public Knowledge and Credibility Perceptions of the FDA as a Tobacco Regulator.
    Schmidt AM; Jarman KL; Ranney LM; Queen TL; Noar SM; Ruel L; Agans R; Hannan A; Goldstein AO
    Nicotine Tob Res; 2018 Sep; 20(11):1310-1316. PubMed ID: 29059369
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.